Ranid 150 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Ziska pharmaceuticals ltd |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients
Pharmacology
Competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Dosage & Administration
- Ranitidine Tablet & Syrup:
- 150 mg twice daily for duodenal and gastric ulcer
- 150 mg twice daily for reflux oesophagitis
- 150 mg 3 times daily for Zollinger Ellison syndrome
- 150 mg twice daily for episodic dyspepsia
- 150 mg at night for maintenance
- 2-4 mg/kg twice daily for children (peptic ulcer)
- Ranitidine IV injection & IV Infusion: Given either as a slow intravenous injection, intermittent intravenous infusion, or intramuscular injection. Dosage for children is 2 mg/kg to 4 mg/kg twice daily.
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide. Minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam, and propranolol. May alter absorption of pH-dependent drugs. May reduce bioavailability with antacids.
Contraindications
Patients hypersensitive to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Pregnancy: Crosses the placenta with no evidence of impaired fertility or harm to the fetus. Should only be used during pregnancy if considered essential.
- Lactation: Excreted in human breast milk. Caution should be exercised when administered to a nursing mother.
Precautions & Warnings
Should be given in reduced dosage to patients with impaired renal and hepatic function.
Use in Special Populations
Use in elderly patients is similar to younger patients in terms of ulcer healing rates and incidence of adverse effects.
Overdose Effects
No particular problems are expected following overdosage. Symptomatic and supportive therapy should be given as appropriate. If required, the drug may be removed from the plasma by haemodiaiysis.
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Slow IV inj: Diluted to a concentration ≤2.5 mg/mL with specific solutions
- Intermittent slow IV infusion: Diluted to a concentration ≤0.5 mg/mL with specific solutions
- Continuous IV infusion: Diluted in specific solutions
- Patients with Zollinger-Ellison syndrome or other hypersecretory conditions: Should be diluted to a concentration ≤2.5 mg/mL with specific solutions
Storage Conditions
Store in a cool and dry place. Protect from light.